METABOLIC RESEARCH RETATRUTIDE 20MG LYOPHILIZED Retatrutide is a triple receptor agonist (GLP-1, GIP, glucagon) investigated in laboratory metabolic-research settings
"One injection isn't gonna do it, but multiple injections over time, I could see where that could become problematic." CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER Paltrow echoed the safety concerns, comparing the current "wild-west" peptide craze to the landscape of supplements in the 90s, "where there's really no third-party testing and it's kind of word of mouth." "Multiple injections over time, I could see where that could become problematic." Both agreed that anyone exploring these therapies should avoid unverified online sources and prioritize working with a medical doctor
They also cant have type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease because those conditions could already be covered by their drug plan and must have one of three conditions, including a body mass index of 35 or higher
GLP-1 medications should be stopped if pancreatitis develops, and should likely be avoided in anyone with pre-existing gastroparesis
repair damaged myocardial tissue
A Phase 2 substudy analyzing body composition found that retatrutide produced up to 26.1% reduction in total body fat mass while limiting lean mass loss to approximately 6.5kg
